For Western blotting assays, the following antibodies were used: A1CF (1:300, ORIGENE, Inc. Rockville, MD, USA, AP50047PU-N), NKRF (1:2000, Proteintech, Inc. Rosemont, IL, USA, 14693-1-AP), IFN-β (1:300, Proteintech, Inc., 27506-1-AP), p65 (1:1000, Cell Signaling Technology, Inc. Danvers, MA, USA, 6956), p50/105 (1:1000, Cell Signaling Technology, Inc., 13586), p-p65 (Ser536) (1:1000, Cell Signaling Technology, Inc., 3033), IκBα (1:1000, Cell Signaling Technology, Inc. 4814), p-IκBα (Ser32) (1:1000, Cell Signaling Technology, Inc., 2859), NPM1 (1:1000, Proteintech, Inc., 60096-1-Ig), β-actin (1:5000, Sigma-Aldrich, Inc. St. Louis, MO, USA, A1978), and GAPDH (1:5000, Sigma-Aldrich, Inc., SAB2701825).
For Immunofluorescence and immunohistochemistry, the following antibodies were used: A1CF (1:50, ORIGENE, Inc., AP50047PU-N), NKRF (1:200, Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA, sc-365568), IFN-β (1:50, Proteintech, Inc., 27506-1-AP), p65 (1:200, Cell Signaling Technology, Inc., 6956), and p-p65(S536) (1:200, Cell Signaling Technology, Inc., 3033).
Liu Y., Yang J., Weng D, & Xie Y. (2024). A1CF Binding to the p65 Interaction Site on NKRF Decreased IFN-β Expression and p65 Phosphorylation (Ser536) in Renal Carcinoma Cells. International Journal of Molecular Sciences, 25(7), 3576.
+ Open protocol